REDWOOD CITY, Calif.
July 23, 2013
/PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), today announced the closing of the public offering of 4,370,000 shares of common stock, including 570,000 shares of common stock which were issued pursuant to the exercise of the underwriters' option to purchase additional shares, at a price of
per share to the public. The total gross proceeds of this offering were approximately
with estimated net proceeds to AcelRx of
after deducting underwriting discounts and commissions and other estimated expenses payable by AcelRx.
Jefferies LLC and
& Co. acted as joint book-running managers for the offering, and Guggenheim Securities acted as co-manager for the offering.
A shelf registration statement on Form S-3 relating to the public offering of the shares of common stock described above was filed with the Securities and Exchange Commission (the "SEC") and is effective. A final prospectus supplement relating to the offering was filed with the SEC and is available on the SEC's web site at
. Copies of the final prospectus supplement may be obtained from the offices of Jefferies LLC, Equity Syndicate Prospectus Department, at 520 Madison Avenue,
New York, New York
, 10022, or by calling (877) 547-6340, or by emailing
, or from
& Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03,
55402 or by calling (800)747-3924, or by emailing
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.